High-risk nodules detected in the hepatobiliary phase of Gd-EOB-DTPA-enhanced mr imaging in cirrhosis or chronic hepatitis: Incidence and predictive factors for hypervascular transformation, preliminary results

Journal of Magnetic Resonance Imaging

Volumn 37, Issue 6, 2013, Pages 1377-1383

  Higaki, Atsushi ^a   Ito, Katsuyoshi ^a   Tamada, Tsutomu ^a   Teruki, Sone ^a   Yamamoto, Akira ^a   Higashi, Hiroki ^a   Kanki, Akihiko ^a   Sato, Tomohiro ^a   Noda, Yasufumi ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (Gd EOB DTPA); hepatocellular carcinoma; magnetic resonance imaging

Indexed keywords

GADOXETIC ACID;

ADULT; AGED; ARTICLE; CHRONIC HEPATITIS; CHRONIC LIVER DISEASE; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CORRELATION ANALYSIS; FEMALE; FOLLOW UP; GROWTH RATE; HEPATOBILIARY RADIOGRAPHY; HIGH RISK PATIENT; HUMAN; LIPID COMPOSITION; LIVER CIRRHOSIS; LIVER NODULE; MALE; MORBIDITY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; OBSERVATIONAL METHOD; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; VASCULARIZATION;

ADULT; AGED; AGED, 80 AND OVER; CELL TRANSFORMATION, NEOPLASTIC; COMORBIDITY; CONTRAST MEDIA; FEMALE; GADOLINIUM DTPA; HEPATITIS, CHRONIC; HUMANS; INCIDENCE; JAPAN; LIVER CIRRHOSIS; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PILOT PROJECTS; PROGNOSIS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY;

EID: 84878263172     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.23933     Document Type: Article

References (32)

1. Vogl TJ, Kümmel S, Hammerstingl R, et al. Liver tumors: comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA. Radiology 1996; 200: 59-67.
2. Hammerstingl R, Huppertz A, Breuer J, et al. Diagnostic efficacy of gadoxetic acid (Primovist)-enhanced MRI and spiral CT for a therapeutic strategy: comparison with intraoperative and histopathologic findings in focal liver lesions. Eur Radiol 2008; 18: 457-467.
3. Halavaara J, Breuer J, Ayuso C, et al. Liver tumor characterization: comparison between liver-specific gadoxetic acid disodiumenhanced MRI and biphasic CT-a multicenter trial. J Comput Assist Tomogr 2006; 30: 345-354.
4. Ahn SS, Kim MJ, Lim JS, Hong HS, Chung YE, Choi JY,. Added value of gadoxetic acid-enhanced hepatobiliary phase MR imaging in the diagnosis of hepatocellular carcinoma. Radiology 2010; 255: 459-466.
5. Reimer P, Rummeny EJ, Daldrup HE, et al. Enhancement characteristics of liver metastases, hepatocellular carcinomas, and hemangiomas with Gd-EOB-DTPA: preliminary results with dynamic MR imaging. Eur Radiol 1997; 7: 275-280.
6. Bluemke DA, Sahani D, Amendola M, et al. Efficacy and safety of MR imaging with liver-specific contrast agent: U.S. multicenter phase III study. Radiology 2005; 237: 89-98.
7. Huppertz A, Balzer T, Blakeborough A, et al. Improved detection of focal liver lesions at MR imaging: multicenter comparison of gadoxetic acid-enhanced MR images with intraoperative findings. Radiology 2004; 230: 266-275.
8. Ichikawa T,. MRI in the evaluation of hepatocellular nodules: role of pulse sequences and contrast agents. Intervirology. 2004; 47: 252-270.
9. Ichikawa T, Saito K, Yoshioka N, et al. Detection and characterization of focal liver lesions: a Japanese phase III, multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced computed tomography predominantly in patients with hepatocellular carcinoma and chronic liver disease. Invest Radiol. 2010; 45: 133-141.
10. Huppertz A, Haraida S, Kraus A, et al. Enhancement of focal liver lesions at gadoxetic acid-enhanced MR imaging: correlation with histopathologic findings and spiral CT-initial observations. Radiology 2005; 234: 468-478.
11. Kitao A, Matsui O, Yoneda N, et al. The uptake transporter OATP8 expression decreases during multistep hepatocarcinogenesis: correlation with gadoxetic acid enhanced MR imaging. Eur Radiol 2011; 21: 2056-2066.
12. Narita M, Hatano E, Arizono S, et al. Expression of OATP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular carcinoma. J Gastroenterol 2009; 44: 793-798.
13. Kumada T, Toyoda H, Tada T, et al. Evolution of hypointense hepatocellular nodules observed only in the hepatobiliary phase of gadoxetate disodium-enhanced MRI. AJR Am J Roentgenol 2011; 197: 58-63.
14. Motosugi U, Ichikawa T, Sano K, et al. Outcome of hypovascular hepatic nodules revealing no gadoxetic acid uptake in patients with chronic liver disease. J Magn Reson Imaging 2011; 34: 88-94.
15. Akai H, Matsuda I, Kiryu S, et al. Fate of hypointense lesions on Gd-EOB-DTPA-enhanced magnetic resonance imaging. Eur J Radiol 2012; 81: 2973-2977.
16. Kogita S, Imai Y, Okada M, et al. Gd-EOB-DTPA-enhanced magnetic resonance images of hepatocellular carcinoma: correlation with histological grading and portal blood flow. Eur Radiol 2010; 20: 2405-2413.
17. Siddique I, El-Naga HA, Madda JP, Memon A, Hasan F,. Sampling variability on percutaneous liver biopsy in patients with chronic hepatitis C virus infection. Scand J Gastroenterol 2003; 38: 427-432.
18. Regev A, Berho M, Jeffers LJ, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002; 97: 2614-2618.
19. Ratziu V, Charlotte F, Heurtier A, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005; 128: 1898-1906.
20. Bedossa P, Dargere D, Paradis V,. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003; 38: 1449-1457.
21. Nakano M, Saito A, Yamamoto M, Doi M, Takasaki K,. Stromal and blood vessel wall invasion in well-differentiated hepatocellular carcinoma. Liver 1997; 17: 41-46.
22. Kondo F, Kondo Y, Nagato Y, Tomizawa M, Wada K,. Interstitial tumour cell invasion in small hepatocellular carcinoma. Evaluation in microscopic and low magnification views. J Gastroenterol Hepatol 1994; 9: 604-612.
23. International Consensus Group for Hepatocellular Neoplasia. Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology 2009; 49: 658-664.
24. Kutami R, Nakashima Y, Nakashima O, Shiota K, Kojiro M,. Pathomorphologic study on the mechanism of fatty change in small hepatocellular carcinoma of humans. J Hepatol 2000; 33: 282-289.
25. Terada T, Nakanuma Y, Hoso M, Saito K, Sasaki M, Nonomura A,. Fatty macroregenerative nodule in non-steatotic liver cirrhosis. A morphologic study. Virchows Arch A Pathol Anat Histopathol 1989; 415: 131-136.
26. Eguchi A, Nakashima O, Okudaira S, Sugihara S, Kojiro M,. Adenomatous hyperplasia in the vicinity of small hepatocellular carcinoma. Hepatology 1992; 15: 843-848.
27. Willatt JM, Hussain HK, Adusumilli S, Marrero JA,. MR Imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversies. Radiology 2008; 247: 311-330.
28. Krinsky GA, Lee VS,. MR imaging of cirrhotic nodules. Abdom Imaging 2000; 25: 471-482.
29. Earls JP, Theise ND, Weinreb JC, et al. Dysplastic nodules and hepatocellular carcinoma: thin-section MR imaging of explanted cirrhotic livers with pathologic correlation. Radiology 1996; 201: 207-214.
30. Kelekis NL, Semelka RC, Woosley JT,. Malignant lesions of the liver with high signal intensity on T1-weighted MR images. J Magn Reson Imaging 1996; 6: 291-294.
31. Kelekis NL, Semelka RC, Worawattanakul S, et al. Hepatocellular carcinoma in North America: a multiinstitutional study of appearance on T1-weighted, T2-weighted, and serial gadolinium-enhanced gradient-echo images. AJR Am J Roentgenol 1998; 170: 1005-1013.
32. Kudo M, Tochio H,. Intranodular blood supply correlates well with biological malignancy grade determined by tumor growth rate in pathologically proven hepatocellular carcinoma. Oncology 2008; 75: 55-64.